Frauke Coppieters

Frauke Coppieters

Auto-generated profile, based on publicly available information

Frauke Coppieters

Department of Biomolecular Medicine, Department of Pharmaceutics, Center for Medical Genetics Ghent, Ghent University, Ghent, Belgium

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2009 in The Lancet
Verified
Journal Article
Closed access
AMAlbert M Maguire
Albert M Maguire
KHKatherine A High
Katherine A High
AAAlberto Auricchio
Alberto Auricchio
JWJ Fraser Wright
J Fraser Wright
EPEric A Pierce
Eric A Pierce
JBJean Bennett
Jean Bennett

5 August 2010 in Human Mutation
Verified
Journal Article
Closed access
PDF file
FCFrauke Coppieters
Frauke Coppieters
SLSteve Lefever
Steve Lefever
BLBart P. Leroy
Bart P. Leroy
Elfride De BaereElfride De Baere
Elfride De Baere
Ciliopathies are an emerging group of disorders, caused by mutations in ciliary genes. One of the most intriguing disease genes associated with ciliopathies is CEP290, in which mutations cause a wide variety of distinct phenotypes, ranging from isolated blindness over Senior‐Loken syndrome (SLS), nephronophthisis (NPHP), Joubert syndrome (related disorders) (JS[RD]), Bardet‐Biedl syndrome (BBS), to the lethal Meckel‐Grüber syndrome (MKS). Despite the identification of over 100 unique CEP290 mutations, no clear genotype–phenotype correlations could yet be established, and consequently the predictive power of a CEP290‐related genotype remains limited. One of the challenges is a better understanding of second‐site modifiers. In this respect, there is a growing interest in the potential modifying effects of variations in genes encoding other members of the ciliary proteome that interact with CEP290. Here, we provide an overview of all CEP290 mutations identified so far, with their associated phenotypes. To this end, we developed CEP290base, a locus‐specific mutation database that links mutations with patients and their phenotypes (medgen.ugent.be/cep290base). Hum Mutat 31:1097–1108, 2010.

1 September 2012 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
SKSusanne Kohl
Susanne Kohl
FCFrauke Coppieters
Frauke Coppieters
FMFrançoise Meire
Françoise Meire
SSSimone Schaich
Simone Schaich
SRSusanne Roosing
Susanne Roosing
BWBernd Wissinger
Bernd Wissinger

3 August 2010 in Human Mutation
Verified
Journal Article
Open access
PDF file
FCFrauke Coppieters
Frauke Coppieters
ICIngele Casteels
Ingele Casteels
FMFrançoise Meire
Françoise Meire
SJSarah De Jaegere
Sarah De Jaegere
SHSally Hooghe
Sally Hooghe
Elfride De BaereElfride De Baere
Elfride De Baere
Leber Congenital Amaurosis (LCA), the most severe inherited retinal dystrophy, is genetically heterogeneous, with 14 genes accounting for 70% of patients. Here, 91 LCA probands underwent LCA chip analysis and subsequent sequencing of 6 genes (CEP290, CRB1, RPE65, GUCY2D, AIPL1and CRX), revealing mutations in 69% of the cohort, with major involvement of CEP290 (30%). In addition, 11 patients with early‐onset retinal dystrophy (EORD) and 13 patients with Senior‐Loken syndrome (SLS), LCA‐Joubert syndrome (LCA‐JS) or cerebello‐oculo‐renal syndrome (CORS) were included. Exhaustive re‐inspection of the overall phenotypes in our LCA cohort revealed novel insights mainly regarding the CEP290‐related phenotype. The AHI1 gene was screened as a candidate modifier gene in three patients with the same CEP290 genotype but different neurological involvement. Interestingly, a heterozygous novel AHI1 mutation, p.Asn811Lys, was found in the most severely affected patient. Moreover, AHI1 screening in five other patients with CEP290‐related disease and neurological involvement revealed a second novel missense variant, p.His758Pro, in one LCA patient with mild mental retardation and autism. These two AHI1 mutations might thus represent neurological modifiers of CEP290‐related disease.

1 July 2007 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
FCFrauke Coppieters
Frauke Coppieters
BLBart P. Leroy
Bart P. Leroy
DBDiane Beysen
Diane Beysen
JHJan Hellemans
Jan Hellemans
KBKarolien De Bosscher
Karolien De Bosscher
Elfride De BaereElfride De Baere
Elfride De Baere

1 April 2017 in Genetics in Medicine
Verified
Journal Article
Open access
DBDorien Baetens
Dorien Baetens
HSHans Stoop
Hans Stoop
FPFrank Peelman
Frank Peelman
ATAnne-Laure Todeschini
Anne-Laure Todeschini
TRToon Rosseel
Toon Rosseel
MCMartine Cools
Martine Cools
We aimed to identify the genetic cause in a cohort of 11 unrelated cases and two sisters with 46,XX SRY-negative (ovo)testicular disorders of sex development (DSD). Whole-exome sequencing (n = 9), targeted resequencing (n = 4), and haplotyping were performed. Immunohistochemistry of sex-specific markers was performed on patients' gonads. The consequences of mutation were investigated using luciferase assays, localization studies, and RNA-seq. We identified a novel heterozygous NR5A1 mutation, c.274C>T p.(Arg92Trp), in three unrelated patients. The Arg92 residue is highly conserved and located in the Ftz-F1 region, probably involved in DNA-binding specificity and stability. There were no consistent changes in transcriptional activation or subcellular localization. Transcriptomics in patient-derived lymphocytes showed upregulation of MAMLD1, a direct NR5A1 target previously associated with 46,XY DSD. In gonads of affected individuals, ovarian FOXL2 and testicular SRY-independent SOX9 expression observed. We propose NR5A1, previously associated with 46,XY DSD and 46,XX primary ovarian insufficiency, as a novel gene for 46,XX (ovo)testicular DSD. We hypothesize that p.(Arg92Trp) results in decreased inhibition of the male developmental pathway through downregulation of female antitestis genes, thereby tipping the balance toward testicular differentiation in 46,XX individuals. In conclusion, our study supports a role for NR5A1 in testis differentiation in the XX gonad.Genet Med 19 4, 367-376.